Field Trials of a Vaccine Against Bovine Mastitis. 2. Evaluation in Two Commercial Dairy Herds

Calzolari, A.; Giraudo, José; Rampone, Horacio; Odierno, Liliana; Giraudo, Ana T.; Frigerio, Cecilia; Bettera, Susana; Raspanti, Claudia; Hernández, Jorge; Wehbe, Mónica; Mattea, M.; Ferrari, Miriam; Larriestra, Alejandro; Nagel, Rosa

doi:10.3168/jds.s0022-0302(97)76007-7

Cited by 32 publications

(14 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several field trials with these and other vaccines including bacterin-toxoid [19,20,21], crude extracts of encapsulated bacteria in aluminum hydroxide [22,23], have revealed a significant degree of protection against mastitis. One of the main goals in vaccination against mastitis is to obtain reduced inflammation at the site of injection, high efficiency against disease, a cost-efficient bacterial inoculum and an immunological parameter that could help to predict the success of vaccination.…”

Section: Introductionmentioning

confidence: 99%

Protection from Staphylococcus aureus mastitis associated with poly-N-acetyl β-1,6 glucosamine specific antibody production using biofilm-embedded bacteria

Pérez

Prenafeta²,

Valle

et al. 2009

Vaccine

View full text Add to dashboard Cite

Staphylococcus aureus vaccines based on bacterins surrounded by slime, surface polysaccharides coupled to protein carriers and polysaccharides embedded in liposomes administered together with non-biofilm bacterins confer protection against mastitis. However, it remains unknown whether protective antibodies are directed to slime-associated known exopolysaccharides and could be produced in the absence of bacterin immunizations. Here, a sheep mastitis vaccination study was carried out using bacterins, crude bacterial extracts or a purified exopolysaccharide from biofilm © 2009 Elsevier Ltd. All rights reserved.Corresponding author: Beatriz Amorena, e Instituto de Agrobiotecnología, CSIC-Universidad Pública de Navarra-Gobierno de Navarra, 31192 Mutilva Baja, Spain. Phone: +34 948 16 80 06; Fax: + 34 948 23 21 91; bamorena@unavarra.es. Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. Disclosed potential conflicts of interestDrs. T. Maira-Litran and G.B. Pier declare they have a financial interest in the form of licensing and consulting income for the commercial development of PNAG-based vaccines and immunotherapies related to issued U.S. patents 7,252,828, 7,015,007, 6,743,431, 6,399,066, 5,980,910, and NIH-PA Author ManuscriptNIH-PA Author Manuscript NIH-PA Author Manuscript bacteria delivered in different vehicles. This polysaccharide reacted specifically with antibodies to poly-N-acetyl-β-1,6-glucosamine (PNAG) and not with antibodies to other capsular antigens or bacterial components. Following intra-mammary challenge with biofilm-producing bacteria, antibody production against the polysaccharide, milk bacterial counts and mastitis lesions were determined. Bacterins from strong biofilm-producing bacteria triggered the highest production of antibodies to PNAG and conferred the highest protection against infection and mastitis, compared with weak biofilm-producing bacteria and non-cellular inocula. Thus, bacterins from strong biofilm bacteria, rather than purified polysaccharide, are proposed as a cost-efficient vaccination against S. aureus ruminant mastitis.

show abstract

Section: Introductionmentioning

confidence: 99%

Protection from Staphylococcus aureus mastitis associated with poly-N-acetyl β-1,6 glucosamine specific antibody production using biofilm-embedded bacteria

Pérez

Prenafeta²,

Valle

et al. 2009

Vaccine

View full text Add to dashboard Cite

show abstract

“…Mastitis due to Staphylococcus aureus is a disease of ruminants that produces substantial economic losses to the dairy industry reaching billions of dollars worldwide [1,2]. Bacterial cell extracts, capsular polysaccharides and/ or toxoids have been included in previously described vaccine preparations to prevent bovine mastitis [1].…”

Section: Introductionmentioning

confidence: 99%

Molecular diversity of live-attenuated prototypic vaccine strains and clinical isolates of Staphylococcus aureus

Buzzola

2001

FEMS Microbiology Letters

View full text Add to dashboard Cite

Bovine mastitis Staphylococcus aureus isolates and prototypic live-attenuated vaccine strains were analyzed by SmaI pulsed-field gel electrophoresis (PFGE) typing and automated ribotyping. The discriminatory index of these methods was 0.91 and 0.69, respectively. SmaI PFGE typing assigned all laboratory strains into cluster Q, which shared 49% similarity with clusters A and B, and 35% similarity with cluster C. Automated ribotyping placed laboratory strains within ribogroups different from those of bovine isolates. These methods have 70% concordance and permitted identification of the prototypic vaccine background from those of clinical isolates. This information is required before conducting field trials with the vaccine. ß

show abstract

“…The ®ndings concerning the prevalence of all intramammary S. aureus infections were con¯icting. No effect of the vaccine was found in the ®eld trial performed by Nordhaug et al (1994a), whereas the prevalence of infection was lowered in the experiments by Giraudo et al (1997) and Calzolari et al (1997) in vaccinated animals compared with control animals.…”

Section: Introductionmentioning

confidence: 86%

Dynamics of Staphylococcus aureus Infections during Vaccination with an Autogenous Bacterin in Dairy Cattle

Hoedemaker

Korff

Edler

et al. 2001

Journal of Veterinary Medicine, Series B

View full text Add to dashboard Cite

The effect of an autogenous vaccine against Staphylococcus aureus on S. aureus prevalence and mastitis, as well as on somatic cell count (SCC), was studied in a dairy herd with a high prevalence of S. aureus. The vaccination group (n = 35; 22 cows and 13 heifers) and the control group (n = 36; 23 cows and 13 heifers) received the vaccine or a placebo, respectively, according to the following protocol: all animals: basic immunization (twice, 3 weeks apart); cows: booster dose at the time of drying off, 5 and 2 weeks before calculated calving date; heifers: booster dose 2 and 5 weeks before calculated calving date. The vaccine or the placebo was administered subcutaneously in the area of the supramammary lymph nodes. Quarter milk samples were collected monthly and subjected to SCC and bacteriological evaluation. At this time, the animals were also checked for signs of clinical mastitis. Non-clinical S. aureus mastitis diagnoses were based on udder quarter SCC and a positive S. aureus culture. In order to compare the SCC in individual whole milk samples, records from the monthly milk quality testing were evaluated. Cow and udder quarter prevalence of S. aureus intramammary infections calculated for the experimental animals and quarters, respectively, did not differ between groups. However, during the lactation period following the boostcr dose, the prevalence of S. aureus increased in both groups (P < 0.05). The cumulative incidence of various mastitis diagnoses (clinical, subclinical, latent infection) due to S. aureus on an animal basis did not differ between groups. On an udder quarter basis, the cumulative incidence of subclinical mastitis was higher in vaccinated animals than in control animals (33.8 versus 26.0%; P < 0.05). This was mainly due to a higher cumulative incidence of subclinical mastitis in vaccinated than control heifers. The SCC in composite milk samples did not differ between groups, but increased as lactation progressed. The herd prevalence of S. aureus differed considerably throughout the study period, but declined consistently to below 10% at the end of the study period. Recent herd checks revealed a prevalence of S aureus infections of < 5%. It is concluded that the autogenous bacterin tested in this study did not have the desired effect on the prevalence of S. aureus infections and mastitis or SCC. The decline in S. aureus prevalence was very probably due to other factors than specific immunization against S. aureus.

show abstract

Field Trials of a Vaccine Against Bovine Mastitis. 2. Evaluation in Two Commercial Dairy Herds

Cited by 32 publications

References 8 publications

Protection from Staphylococcus aureus mastitis associated with poly-N-acetyl β-1,6 glucosamine specific antibody production using biofilm-embedded bacteria

Protection from Staphylococcus aureus mastitis associated with poly-N-acetyl β-1,6 glucosamine specific antibody production using biofilm-embedded bacteria

Molecular diversity of live-attenuated prototypic vaccine strains and clinical isolates of Staphylococcus aureus

Dynamics of Staphylococcus aureus Infections during Vaccination with an Autogenous Bacterin in Dairy Cattle

Contact Info

Product

Resources

About